Letter to the Editor: Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease.,Metabolism

当前位置： X-MOL 学术 › Metabolism › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Letter to the Editor: Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease.
Metabolism ( IF 10.8 ) Pub Date : 2020-04-19 , DOI: 10.1016/j.metabol.2020.154244
Kenneth I Zheng ₁ , Feng Gao ₂ , Xiao-Bo Wang ₃ , Qing-Feng Sun ₄ , Ke-Hua Pan ₅ , Ting-Yao Wang ₆ , Hong-Lei Ma ₁ , Yong-Ping Chen ₁ , Wen-Yue Liu ₇ , Jacob George ₈ , Ming-Hua Zheng ₉

Affiliation

MAFLD Research Center, Department of Hepatology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Department of Gastroenterology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Department of Critical Care Medicine, Wenzhou Central Hospital, Wenzhou, China.
Department of Infectious Diseases, Ruian People's Hospital, Wenzhou, China.
Department of Radiology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Department of Nephrology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Department of Endocrinology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, Sydney, Australia.
MAFLD Research Center, Department of Hepatology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China; Institute of Hepatology, Wenzhou Medical University, Wenzhou, China; Key Laboratory of Diagnosis and Treatment for The Development of Chronic Liver Disease in Zhejiang Province, Wenzhou, China.

BACKGROUND & AIMS Coronavirus disease 2019 (COVID-19) has been declared a pandemic in 2020. Patients with metabolic associated fatty liver disease (MAFLD) are often obese and have additional metabolic risk factors which may aggravate the severity of respiratory diseases and of COVID-19. This study aims to investigate the association between MAFLD and COVID-19 severity. METHODS 214 patients with laboratory-confirmed COVID-19 aged between 18 and 75 years from three hospitals in Wenzhou, China were consecutively enrolled. Sixty-six patients with MAFLD were included in the final analysis. COVID-19 was diagnosed as a positive result by high-throughput sequencing or real-time reverse transcriptase-polymerase chain reaction assay of oropharyngeal swab specimens. COVID-19 severity was assessed during hospitalization and classified as severe and non-severe based on the current management guideline. All patients were screened for fatty liver by computed tomography and subsequently diagnosed as MAFLD according to a recent set of consensus diagnostic criteria. Obesity was defined as BMI >25 kg/m2. RESULTS The presence of obesity in MAFLD patients was associated with a ~ 6-fold increased risk of severe COVID-19 illness (unadjusted-OR 5.77, 95% CI 1.19-27.91, p = .029). Notably, this association with obesity and COVID-19 severity remained significant (adjusted-OR 6.32, 95% CI 1.16-34.54, p = .033) even after adjusting for age, sex, smoking, diabetes, hypertension, and dyslipidaemia. CONCLUSIONS Our data demonstrate that the risk of obesity to COVID-19 severity is greater in those with, than those without MAFLD.

更新日期：2020-04-19

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文